GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » Total Equity

BioMerieux (XPAR:BIM) Total Equity : €3,880 Mil (As of Jun. 2024)


View and export this data going back to 2004. Start your Free Trial

What is BioMerieux Total Equity?

BioMerieux's total equity for the quarter that ended in Jun. 2024 was €3,880 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BioMerieux Total Equity Historical Data

The historical data trend for BioMerieux's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Total Equity Chart

BioMerieux Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,254.60 2,481.30 3,163.60 3,642.90 3,752.20

BioMerieux Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,513.90 3,642.90 3,641.50 3,752.20 3,880.10

BioMerieux Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BioMerieux's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=5259.2-1507
=3,752

BioMerieux's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=5319.1-1439
=3,880

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMerieux Total Equity Related Terms

Thank you for viewing the detailed overview of BioMerieux's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMerieux Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » Total Equity
Comparable Companies
XPAR:ERF XPAR:LBIRD XPAR:ALPRE TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA LH SHSE:603259 DGX ICLR RVTY MEDP CRL
Traded in Other Exchanges
BMXMF:USA BIMp:UK 0RUG:UK EYWN:Germany
Address
Marcy l’Etoile, Lyon, FRA, 69280
Website
http://www.biomerieux.com
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.

BioMerieux Headlines

No Headlines